Cargando…
Beyond IgE—When Do IgE-Crosslinking and Effector Cell Activation Lead to Clinical Anaphylaxis?
Anaphylaxis in humans is inherently difficult to study due to the acuteness of symptoms and the lack of biomarkers serving as risk predictors. Most cases are related to IgE sensitizations to foods, insect venoms, and drugs with mastocytosis patients forming a smaller risk group. However, identifying...
Autores principales: | Poulsen, Lars K., Jensen, Bettina M., Esteban, Vanesa, Garvey, Lene Heise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554325/ https://www.ncbi.nlm.nih.gov/pubmed/28848540 http://dx.doi.org/10.3389/fimmu.2017.00871 |
Ejemplares similares
-
Animal Models of IgE Anaphylaxis
por: Gouel-Chéron, Aurélie, et al.
Publicado: (2023) -
Pediatric anaphylaxis and hyper IgE syndrome
por: Dosanjh, Amrita
Publicado: (2017) -
Allergy, Anaphylaxis, and Nonallergic Hypersensitivity: IgE, Mast Cells, and Beyond
por: Vitte, Joana, et al.
Publicado: (2022) -
Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010) -
Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
por: Hu, Jiayun, et al.
Publicado: (2018)